Original Article
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Tofacitinib, un inhibidor oral de la quinasa Janus, para el tratamiento de artritis reumatoide en pacientes de Latinoamérica: eficacia y seguridad de estudios fase 3 y de extensión a largo plazo
Sebastião Cezar Radominskia, Mario Humberto Cardielb, Gustavo Citerac, Annelise Goecked, Juan Jose Jallere, Andrea Barranjard Vannucci Lomontef, Pedro Mirandag, Patricia Velezh, Daniel Xibilléi, Kenneth Kwokj, Ricardo Rojok,
, Erika Gabriela Garcíal
Corresponding author
a Universidade Federal do Paraná, Curitiba, Brazil
b Centro de Investigación Clínica de Morelia, Morelia, Mexico
c Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
d Instituto de Ciencias Biomédicas, Hospital Clínico de la Universidad de Chile, Santiago, Chile
e University Metropolitana, Barranquilla, Colombia
f Hospital Heliópolis, São Paulo, Brazil
g Centro de Estudios Reumatológicos, Santiago, Chile
h CIREISAS, Bogotá, Colombia
i Hospital General de Cuernavaca, Cuernavaca, Mexico
j Pfizer Inc, New York, NY, USA
k Pfizer Inc, Groton, CT, USA
l Pfizer Inc, Collegeville, PA, USA
Ver másRead
5532
Timeswas read the article
2338
Total PDF
3194
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 0 | 10 | 10 |
| 2025 5 | 90 | 58 | 148 |
| 2025 4 | 87 | 29 | 116 |
| 2025 3 | 101 | 43 | 144 |
| 2025 2 | 74 | 32 | 106 |
| 2025 1 | 96 | 36 | 132 |
| 2024 12 | 64 | 33 | 97 |
| 2024 11 | 66 | 71 | 137 |
| 2024 10 | 66 | 44 | 110 |
| 2024 9 | 38 | 20 | 58 |
| 2024 8 | 70 | 62 | 132 |
| 2024 7 | 61 | 38 | 99 |
| 2024 6 | 50 | 38 | 88 |
| 2024 5 | 64 | 44 | 108 |
| 2024 4 | 60 | 25 | 85 |
| 2024 3 | 40 | 41 | 81 |
| 2024 2 | 33 | 29 | 62 |
| 2024 1 | 27 | 25 | 52 |
| 2023 12 | 23 | 32 | 55 |
| 2023 11 | 26 | 39 | 65 |
| 2023 10 | 53 | 29 | 82 |
| 2023 9 | 120 | 41 | 161 |
| 2023 8 | 30 | 21 | 51 |
| 2023 7 | 32 | 27 | 59 |
| 2023 6 | 29 | 31 | 60 |
| 2023 5 | 39 | 34 | 73 |
| 2023 4 | 45 | 24 | 69 |
| 2023 3 | 62 | 33 | 95 |
| 2023 2 | 46 | 33 | 79 |
| 2023 1 | 32 | 25 | 57 |
| 2022 12 | 62 | 40 | 102 |
| 2022 11 | 65 | 38 | 103 |
| 2022 10 | 36 | 53 | 89 |
| 2022 9 | 42 | 41 | 83 |
| 2022 8 | 32 | 46 | 78 |
| 2022 7 | 29 | 38 | 67 |
| 2022 6 | 44 | 34 | 78 |
| 2022 5 | 39 | 34 | 73 |
| 2022 4 | 44 | 26 | 70 |
| 2022 3 | 41 | 46 | 87 |
| 2022 2 | 34 | 44 | 78 |
| 2022 1 | 52 | 49 | 101 |
| 2021 12 | 41 | 37 | 78 |
| 2021 11 | 40 | 49 | 89 |
| 2021 10 | 58 | 47 | 105 |
| 2021 9 | 33 | 45 | 78 |
| 2021 8 | 22 | 39 | 61 |
| 2021 7 | 14 | 25 | 39 |
| 2021 6 | 19 | 23 | 42 |
| 2021 5 | 38 | 35 | 73 |
| 2021 4 | 100 | 58 | 158 |
| 2021 3 | 76 | 36 | 112 |
| 2021 2 | 30 | 21 | 51 |
| 2021 1 | 27 | 14 | 41 |
| 2020 12 | 42 | 25 | 67 |
| 2020 11 | 24 | 16 | 40 |
| 2020 10 | 18 | 11 | 29 |
| 2020 9 | 36 | 26 | 62 |
| 2020 8 | 64 | 27 | 91 |
| 2020 7 | 22 | 20 | 42 |
| 2020 6 | 38 | 14 | 52 |
| 2020 5 | 35 | 11 | 46 |
| 2020 4 | 16 | 18 | 34 |
| 2020 3 | 10 | 4 | 14 |
| 2020 2 | 2 | 0 | 2 |
| 2018 12 | 2 | 0 | 2 |
| 2018 5 | 2 | 3 | 5 |
| 2018 4 | 31 | 7 | 38 |
| 2018 3 | 38 | 10 | 48 |
| 2018 2 | 17 | 8 | 25 |
| 2018 1 | 13 | 12 | 25 |
| 2017 12 | 21 | 20 | 41 |
| 2017 11 | 18 | 15 | 33 |
| 2017 10 | 25 | 28 | 53 |
| 2017 9 | 7 | 16 | 23 |
| 2017 8 | 35 | 37 | 72 |
| 2017 7 | 36 | 45 | 81 |
Show all
